Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
Seaport Therapeutics appointed Dr. Sharon Mates, the founder and former CEO of Intra-Cellular Therapies, to its Board of Directors. Dr. Mates brings decades of experience, having guided Intra-Cellular through the commercialization of CAPLYTA and its eventual $14.6 billion acquisition by Johnson & Johnson.
Key figures
- Intra cellular acquisition value
- $14.6 billion
- Caplyta sales prior to acquisition
- greater than $1.5 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.